Page 2 - Torrent Pharmaceuticals

Strong profit growth keeps brokerages positive on Torrent Pharma

Led by an 18% y-o-y growth in the domestic formulations segment, which accounts for over half its overall revenues, the company posted 16% growth at a consolidated level

Torrent Pharma Q2 results: Profit after tax up 24% to Rs 386 crore

The company exhibited a 2.66 per cent increase in revenue and was able to turn around the PAT by 2.09 per cent

Torrent lines up at least $5 billion funding to buy 33% stake in Cipla

Torrent has secured commitments from a group of overseas banks for a potential deal, the people said, asking not to be identified as the information is not public

Torrent promoters may pledge stake in power arm to fund Cipla buy

Torrent's promoters own a 53.6 per cent stake in Torrent Power, valued at Rs 18,643 crore as of Friday, which remains a crucial avenue for raising funds for the Mehtas

Cipla, Torrent may need to divest 15 brands in buyout deal: Bernstein

Torrent has a strong presence in gastrointestinal, neurology, and cardiac segments

Torrent leads race to acquire Cipla with 30% higher offer than Blackstone's

Shares of Cipla closed at Rs 1,239 apiece on the BSE on Monday, with a market valuation of Rs 1 trillion

Torrent Pharma gears up to buyout Cipla promoters, approach PE funding

Torrent Pharma might pay a total of Rs 60,000 crore (around $7.2 billion) for a 59.47 per cent stake in the 88-year-old pharmaceutical company

Torrent Pharmaceuticals gets EIR from USFDA for Gujarat's Dahej facility

The Dahej facility manufactures Active Pharmaceutical Ingredients (APIs) and formulations for Torrent Pharma's international markets

Stocks to Watch: Reliance, Coforge, GAIL, Vascon, Sugar stocks, P&G Health

Stocks to Watch on August 24, 2023: Coforge promoter Hulst BV is looking to offload its entire 26.63% stake in the firm via a block deal; India may ban sugar exports for the first time in 7 years

USFDA grants VAI classification to Torrent's Gujarat manufacturing site

The US health regulator has granted Voluntary Action Indicated classification to Torrent Pharmaceutical's manufacturing site in Dahej, Gujarat. A VAI classification means objectionable conditions or practices were found but the agency is not prepared to take or recommend any administrative or regulatory action. As per the information available on its website, the United States Food and Drug Administration (USFDA) has granted Voluntary Action Indicated (VAI) classification to the plant. The Dahej site was earlier placed under 'Official Action Indicated (OAI)' classification based on a March 2019 inspection outcome. OAI means "objectionable conditions were found and regulatory administrative sanctions by FDA are indicated" during inspections. The Dahej site was re-inspected by the USFDA between May 17 and May 25, 2023 and the officials had issued Form 483 with two observations. Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has ..

Torrent Group capitalisation tops Rs 1 trn fuelled by acquisitions, EV push

India's leading diversified business conglomerate Torrent Group has crossed Rs 1 lakh crore market capitalisation as it's power units EV push and pharma company's recent acquisitions fuelled a rally in stocks. The combined market capitalisation of its two listed group companies - Torrent Pharmaceuticals Ltd and Torrent Power Ltd crossed the Rs 1 lakh crore mark in trading on Monday, according to stock exchange information. Torrent Pharmaceuticals shares hit an intra-day high of Rs 2,014.8 before closing at Rs 2,010 on the NSE. This gave it a market capitalisation of over Rs 68,000 crore. The shares of Torrent Power hit an intraday high of Rs 682 before closing at Rs 678.20, giving it a market capitalisation of Rs about Rs 32,600 crore. The combined market capitalisation of the Group now stands at Rs 1,00,600 crore. The Group's valuation hit Rs 50,000 crore in February 2020. This shows 2x growth in market capitalisation in the past three years - driven by robust financial performan

Torrent Pharma reports Q4 net profit of Rs 287 crore, revenue up 16%

The company's consolidated revenue from operation rose by 16.8 per cent to Rs 2,491 crore for the March quarter as compared to Rs 2,131 crore in the year-ago period

Torrent Pharmaceuticals forays into OTC segment with calcium supplement

Torrent Pharmaceuticals on Tuesday said it has forayed into the over-the-counter segment in the country with Shelcal 500, a calcium supplement brand. With its composition of 500mg Calcium and 250 IU of Vitamin D3, Shelcal 500 helps optimise calcium absorption, increases bone density, improves muscle strength and helps boost immunity. The calcium is sourced from natural ingredients like oyster shell, having good absorption/bioavailability in the body. "With Shelcal's entry into OTC, the brand is poised to become the largest calcium supplement brand in India," Torrent Pharmaceuticals Director Aman Mehta said in a statement. According to studies, 40.6 per cent of Indians are calcium-deficient, while 79 per cent are Vitamin D-deficient.

Torrent Pharma Q3 PAT up 14% to Rs 249 crore riding on India, Brazil

Torrent Pharma's revenues came in at Rs 2,491 crore for the quarter under review. The Ebitda margins were at 29.1 per cent while gross margins were 71 per cent during Q3FY23

Torrent Pharma Q3 net profit up 14% to Rs 283 cr; interim dividend declared

Torrent Pharma on Wednesday said its consolidated net profit increased by 14 per cent to Rs 283 crore in the third quarter ended December 31, 2022. The drug firm had reported a net profit of Rs 249 crore in the October-December period of previous fiscal. Net sales increased to Rs 2,459 crore in the quarter under review as against Rs 2,092 crore in the year-ago period, the company said in a regulatory filing. The company's board, which met on Wednesday, declared an interim dividend of Rs 14 (280 per cent) per share of Rs 5 each. On Wednesday, shares of the company ended 1.86 per cent down at Rs 1,557.50 apiece on the BSE.

Top Headlines: Reliance to acquire METRO AG's India biz, Covid-19 alert

Business Standard brings you the top headlines at this hour

After the anti-diabetic market, India's cardiac market in for a shake-up

After the anti-diabetic market, India's cardiac market in for a shake-up

World in turmoil, domestic pharma firms target India for healthy growth

Share of India revenue in home-grown firms' consolidated turnover rising over the years

Number of deals down 42% in October but matches pre-pandemic level: Report

According to GT Bharat's monthly Dealtracker, the biggest deal in October was Torrent Pharma's $250 million acquisition of Curatio Healthcare

Nifty Pharma index surpasses 200-DMA; Cipla, Granules can soar up to 15%

The Pharma benchmark has outperformed the overall market in recent trading sessions; sustenance above 200-DMA is likely to trigger further gains for it